Topical effectiveness of molgramostim (GM-CSF) in sickle cell leg ulcers.
BACKGROUND
Leg ulcers are a frequently neglected, severe complication of sickle cell disease (SCD), responsible for significant altering quality of life. The management of leg ulcers remains disappointing. Local application of recombinant human granulocyte-macrophage colony-stimulating factor has been shown to be effective in several types of chronic wound healing.


METHODS
We report 5 homozygous sickle cell patients with 14 leg ulcers lasting from 1 month to 6 years, treated with topical dripping of molgramostim solution.


RESULTS
Healing was obtained for 9/14 ulcers, with no local or systemic adverse reactions.


CONCLUSIONS
Molgramostim solution appears to be an adequate therapy for SCD leg ulcers but a more conclusive evaluation will depend on larger series of patients and other types of formulations for topical applications could be even more effective in the future.
Méry
Laure
L
Service de Dermatologie, Hôpital Tenon, Paris, France. laurepat@wanadoo.fr
Girot
Robert
R
Aractingi
Sélim
S
D000287:Administration, Topical; D000328:Adult; D000755:Anemia, Sickle Cell / Q000150:complications* / Q000175:diagnosis; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage*; D006801:Humans; D007871:Leg Ulcer / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D011379:Prognosis; D011994:Recombinant Proteins / Q000008:administration & dosage*; D012494:Sampling Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects / Q000502:physiology
D011994:Recombinant Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; C082430:molgramostim